placebo, 2%).
All other grade 3 to 4 adverse events occurred in 2% or less of patients.
After a median follow-up of 5.2 years (interquartile range, 2.1–5.3), patients in the neratinib group had significantly fewer IDFS events than those in the placebo group (neratinib group, 116 events vs.
placebo group, 163 events; stratified HR, 0.73; 95% CI, 0.57–0.92;P= .0083).
The 5-year IDFS rate was 90.2% (95% CI, 88.3%–91.8%) in the neratinib group and 87.7% (85.7%–89.4%) in the placebo group.[143] OS data are not mature.
The most common grade 1 to 2 adverse events included diarrhea (neratinib, 55% vs.
placebo, 34%), nausea (41% vs.